Pliant Therapeutics

Integrin target selected for development under 2019 collaboration following successful validation by PliantPliant to receive $4 million milestone payment and reimbursement in support of…

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel…

$100 million Oxford loan facility extends cash runway to mid-2024 FDA Fast Track designation granted to PLN-74809 in IPF INTEGRIS-IPF Phase 2a data readout in mid-2022 EMA Orphan Drug…

Five posters include data across biomarker, target engagement, and mechanism studies supporting development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF…

SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing…

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel…

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, February 28th by Pliant Therapeutics, Inc. (Nasdaq: PLRX), please…

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg Trial…

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel…

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing…